Table 2.

Crude and adjusted Cox proportional hazard ratios for doubling of baseline serum creatinine level in 707 type 2 diabetic patients with nephropathy stratified by CKD stage according to each equation.

	HR	95% CI	P		HR	95% CI	P
CKDMDRD			<0.0001	CKDCKD-EPI			<0.0001
Stage 1: ≥90	1	Reference		Stage 1: ≥90	1	Reference
Stage 2: 60–89	1.54	0.72–3.32	0.2679	Stage 2: 60–89	1.90	0.97–3.73	0.0630
Stage 3a: 45–59	1.79	0.79–4.07	0.1658	Stage 3a: 45–59	2.18	1.04–4.55	0.0383
Stage 3b: 30–44	4.11	1.92–8.82	0.0003	Stage 3b: 30–44	4.31	2.19–8.48	<0.0001
Stage 4: 15–29	4.40	2.04–9.49	0.0002	Stage 4: 15–29	5.08	2.56–10.08	<0.0001
Stage 5: <15	6.64	2.66–16.61	<0.0001	Stage 5: <15	8.09	3.65–17.95	<0.0001
Adjusted model 1			<0.0001	Adjusted model 1			<0.0001
Stage 1: ≥90	1	Reference		Stage 1: ≥90	1	Reference
Stage 2: 60–89	1.13	0.57–2.21	0.7311	Stage 2: 60–89	1.56	0.84–2.89	0.1564
Stage 3a: 45–59	1.73	0.85–3.51	0.1324	Stage 3a: 45–59	2.42	1.26–4.67	0.0083
Stage 3b: 30–44	3.63	1.83–7.18	0.0002	Stage 3b: 30–44	4.29	2.29–8.02	<0.0001
Stage 4: 15–29	4.20	2.10–8.37	<0.0001	Stage 4: 15–29	5.47	2.89–10.35	<0.0001
Stage 5: <15	5.83	2.62–12.98	<0.0001	Stage 5: <15	8.17	3.98–16.78	<0.0001
Adjusted model 2			<0.0001	Adjusted model 2			<0.0001
Stage 1: ≥90	1	Reference		Stage 1: ≥90	1	Reference
Stage 2: 60–89	1.12	0.55–2.28	0.7493	Stage 2: 60–89	1.70	0.88–3.28	0.1139
Stage 3a: 45–59	1.63	0.77–3.43	0.2013	Stage 3a: 45–59	2.32	1.14–4.70	0.0199
Stage 3b: 30–44	3.40	1.64–7.07	0.0010	Stage 3b: 30–44	4.39	2.22–8.67	<0.0001
Stage 4: 15–29	3.60	1.73–7.51	0.0006	Stage 4: 15–29	5.08	2.55–10.13	<0.0001
Stage 5: <15	5.34	2.27–12.55	0.0001	Stage 5: <15	7.79	3.57–17.02	<0.0001
Adjusted model 3			<0.0001	Adjusted model 3			<0.0001
Stage 1: ≥90	1	Reference		Stage 1: ≥90	1	Reference
Stage 2: 60–89	1.09	0.54–2.23	0.8093	Stage 2: 60–89	1.67	0.86–3.23	0.1270
Stage 3a: 45–59	1.49	0.70–3.18	0.2978	Stage 3a: 45–59	2.14	1.04–4.39	0.0379
Stage 3b: 30–44	3.42	1.64–7.12	0.0010	Stage 3b: 30–44	4.43	2.24–8.76	<0.0001
Stage 4: 15–29	3.60	1.72–7.53	0.0007	Stage 4: 15–29	5.14	2.57–10.28	<0.0001
Stage 5: <15	5.39	2.26–12.88	0.0001	Stage 5: <15	8.00	3.62–17.68	<0.0001
Adjusted model 4			<0.0001	Adjusted model 4			<0.0001
Stage 1: ≥90	1	Reference		Stage 1: ≥90	1	Reference
Stage 2: 60–89	1.25	0.56–2.81	0.5848	Stage 2: 60–89	1.90	0.91–3.97	0.0874
Stage 3a: 45–59	1.44	0.60–3.46	0.4159	Stage 3a: 45–59	2.12	0.94–4.75	0.0688
Stage 3b: 30–44	3.22	1.40–7.43	0.0060	Stage 3b: 30–44	4.03	1.88–8.63	0.0003
Stage 4: 15–29	3.22	1.43–7.71	0.0051	Stage 4: 15–29	4.77	2.19–10.37	0.0001
Stage 5: <15	6.71	2.51–17.91	0.0001	Stage 5: <15	9.82	4.05–23.80	<0.0001

CKD: chronic kidney disease; HR: hazard ratio; CI: confidence interval; MDRD: modification of diet in renal disease; CKD-EPI: chronic kidney disease epidemiology collaboration.

Model 1: adjusted for age and sex.

Model 2: adjusted for age, sex, and duration of diabetes.

Model 3: adjusted for age, sex, duration of diabetes, and baseline HbA1c level.

Model 4: adjusted for age, sex, duration of diabetes, baseline HbA1c level, and medication for hypertension.